Different involvement of the megakaryocytic lineage by the JAK2V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis

Annals of Hematology

Volumn 86, Issue 4, 2007, Pages 245-253

  Hussein, Kais ^a   Brakensiek, Kai ^a   Buesche, Guntram ^a   Buhr, Thomas ^a   Wiese, Birgit ^a   Kreipe, Hans ^a   Bock, Oliver ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

JAK2 V617F mutation; Laser microdissection; Megakaryocytes; Philadelphia chromosome negative chronic myeloproliferative disorders

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2;

ADULT; AGED; ALLELE; ARTICLE; BONE MARROW BIOPSY; CELL ISOLATION; CELL LINEAGE; CONTROLLED STUDY; DNA EXTRACTION; ERYTHROCYTE COUNT; FEMALE; FOLLOW UP; GENE DOSAGE; GENE MUTATION; GENETIC ASSOCIATION; HEMATOCRIT; HOMOZYGOSITY; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MEGAKARYOCYTE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; BONE MARROW; CELL LINEAGE; CHRONIC DISEASE; DNA MUTATIONAL ANALYSIS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENOTYPE; HUMANS; JANUS KINASE 2; MALE; MEGAKARYOCYTES; MIDDLE AGED; MUTANT PROTEINS; MUTATION; MYELOFIBROSIS; PHENOTYPE; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 33847646272     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0252-3     Document Type: Article

References (26)

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Cancer Genome Project (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061
2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148
3. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397
4. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790
5. Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, Hasselbalch HC, Larsen TS, Pallisgaard N, Giraudier S, Le Bousse-Kerdiles MC, Desterke C, Guerton B, Dupriez B, Bordessoule D, Fenaux P, Kiladjian JJ, Viallard JF, Briere J, Harrison CN, Green AR, Reilly JT (2006) The V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107:2098-2100
6. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162-2168
7. Tefferi A (2005) Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 23:8520-8530
8. Le Bousse-Kerdiles MC, Martyre MC (1999) Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 78:437-444
9. Buhr T, Büsche G, Choritz H, Länger F, Kreipe H (2003) Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 119:152-158
10. Thiele J, Kvasnicka HM (2004) Prefibrotic chronic idiopathic myelofibrosis - a diagnostic enigma? Acta Haematol 111:155-159
11. Bock O, Schlue J, Mengel M, Buesche G, Serinsoez E, Kreipe H (2004) Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders. J Pathol 203:609-615
12. Lehmann U, Kreipe H (2001) Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 25:409-418
13. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106:3370-3373
14. Bock O, Buesche G, Koop C, Schroeter S, Buhr T, Kreipe H (2006) Detection of the single hotspot mutation in the pseudokinase domain JH2 of Janus kinase 2 (JAK2) in bone marrow trephine biopsies from chronic myeloproliferative disorders. J Mol Diagnostics 8:170-177
15. Tefferi A, Lasho TL, Gilliland G (2005) JAK2 mutations in myeloproliferative disorders. N Engl J Med 353:1416-1417
16. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, Gilliland DG, Tefferi A (2005) JAK2 mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance. Br J Haematol 131:208-213
17. Horn T, Kremer M, Dechow T, Pfeifer WM, Geist B, Perker M, Duyster J, Quintanilla-Martinez L, Fend F (2006) Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases. J Mol Diagnostics 8:299-304
18. Florensa L, Bellosillo B, Besses C, Puigdecanet E, Espinet B, Perez-Vila E, Longaron R, Vila RM, Sole F, Serrano S (2006) JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients. Leukemia 20:1903-1905
19. Fakhrai-Rad H, Pourmand N, Ronaghi M (2002) Pyrosequencing: An accurate detection platform for single nucleotide polymorphisms. Human Mutat 19:479-485
20. Kiladjian JJ, Elkassar N, Cassinat B, Hetet G, Giraudier S, Balitrand N, Conejero C, Briere J, Fenaux P, Chomienne C, Grandchamp B (2006) Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia 20:1181-1183
21. Zehentner BK, Loken MR, Wells DA (2006) JAK2(V617F) mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders. Am J Hematol 81:806-807
22. Bock O, Neuse J, Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H (2006) Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol 169:471-481
23. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D (2005) The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: Lineage specificity and clinical correlates. Br J Haematol 131:320-328
24. Mesa RA, Powell H, Lasho T, DeWald GW, McClure R, Tefferi A (2005) A longitudinal study of the JAK2 (V617F) mutation in myelofibrosis with myeloid metaplasia: Analysis at two time points. Haematologica 91:415-416
25. Yip SF, So CC, Chan AY, Liu HY, Wan TK, Chan LC (2006) The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis. Leukemia 20:1165
26. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, Menot ML, Massonnet G, Dutel JL, Ghomari K, Rousselot P, Grange MJ, Chait Y, Vainchenker W, Parquet N, Abdelkader-Aljassem L, Bernard JF, Rain JD, Chevret S, Chomienne C, Fenaux P (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108:2037-2040